Your browser doesn't support javascript.
loading
[Cost-effectiveness of consolidation treatments for acute myeloid leukemia in high-risk pediatric patients within the Colombian healthcare system]. / Costo-efectividad de los tratamientos de consolidación para la leucemia mieloide aguda en niños en riesgo alto en el sistema de salud colombiano.
García, Mario; Chicaíza, Liliana Alejandra; Quitián, Hoover; Linares, Adriana; Ramírez, Óscar.
Afiliación
  • García M; Facultad de Ciencias Económicas, Universidad Nacional de Colombia, Bogotá, D.C, Colombia.
  • Chicaíza LA; Facultad de Ciencias Económicas, Universidad Nacional de Colombia, Bogotá, D.C, Colombia.
  • Quitián H; Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, D.C, Colombia.
  • Linares A; Facultad de Medicina, Universidad Nacional de Colombia, Bogotá, D.C, Colombia.
  • Ramírez Ó; Centro Médico Imbanaco, Unidad de Trasplante de Médula Ósea, Cali, Colombia.
Biomedica ; 35(4): 549-56, 2015.
Article en Es | MEDLINE | ID: mdl-26844444
INTRODUCTION: Acute myeloid leukemia represents about 20% of leukemias in minors under 18 years old. At present, there are only two consolidation treatment alternatives: Chemotherapy and stem-cell transplantation. OBJECTIVE: To evaluate the cost-effectiveness of unrelated and related hematopoietic stem cell transplantations, versus chemotherapy consolidation in pediatric patients with high-risk acute myeloid leukemia. MATERIALS AND METHODS: A decision tree was constructed with life-years gained as the outcome. Costs and probabilities were extracted from the literature. Probabilistic sensitivity analyses and acceptability curves were computed. The cost-effectiveness threshold was three times the 2010 per capita gross domestic product. RESULTS: When compared to consolidation chemotherapy cycles, related and unrelated hematopoietic stem-cell transplantation had incremental cost-effectiveness ratios of COP$ 9,226,421 (USD$ 4,820) and COP$ 6,544,116 (USD$ 3,419) respectively, which are lower than the per capita gross domestic product (COP$ 12,047,418, USD$ 6,294). Transplant proved to be cost-effective in 70% of the simulations and had a higher probability of the willingness to pay being over than COP$ 7,200,000 (USD$ 3,762). CONCLUSION: In Colombia, related and unrelated hematopoietic stem-cell transplants are cost-effective alternatives to consolidation treatment for high-risk acute myeloid leukemia in pediatric patients.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre Hematopoyéticas / Quimioterapia de Consolidación Tipo de estudio: Etiology_studies / Evaluation_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adolescent / Child / Child, preschool / Humans País/Región como asunto: America do sul / Colombia Idioma: Es Revista: Biomedica Año: 2015 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Colombia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Protocolos de Quimioterapia Combinada Antineoplásica / Trasplante de Células Madre Hematopoyéticas / Quimioterapia de Consolidación Tipo de estudio: Etiology_studies / Evaluation_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Aspecto: Patient_preference Límite: Adolescent / Child / Child, preschool / Humans País/Región como asunto: America do sul / Colombia Idioma: Es Revista: Biomedica Año: 2015 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Colombia